7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
- Product Name
- 7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
- CAS No.
- 1633350-06-7
- Chemical Name
- 7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
- Synonyms
- BGB-3111;EOS-61237;(±)-BGB3111);(±)-BGB 3111;BGB3111; BGB 3111;Zanubrutinib Racemate;(±)-Zanubrutinib ((±)-BGB-3111;(±)-Zanubrutinib, 10 mM in DMSO;(±)Zanubrutinib,(±) Zanubrutinib;7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
- CBNumber
- CB53142878
- Molecular Formula
- C27H29N5O3
- Formula Weight
- 471.55
- MOL File
- 1633350-06-7.mol
7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Property
- Boiling point:
- 713.4±60.0 °C(Predicted)
- Density
- 1.33±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO : ≥ 30 mg/mL (63.62 mM);Ethanol : ≥ 10 mg/mL (21.21 mM)
- form
- Solid
- pka
- 15.35±0.40(Predicted)
- color
- White to light yellow
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P271Use only outdoors or in a well-ventilated area.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P312Call a POISON CENTER or doctor/physician if you feel unwell.
P321Specific treatment (see … on this label).
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
P362Take off contaminated clothing and wash before reuse.
P403+P233Store in a well-ventilated place. Keep container tightly closed.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- CS-6366
- Product name
- (±)-Zanubrutinib
- Purity
- 99.70%
- Packaging
- 5mg
- Price
- $140
- Updated
- 2021/12/16
- Product number
- CS-6366
- Product name
- (±)-Zanubrutinib
- Purity
- 99.70%
- Packaging
- 10mg
- Price
- $220
- Updated
- 2021/12/16
- Product number
- CS-6366
- Product name
- (±)-Zanubrutinib
- Purity
- 99.70%
- Packaging
- 50mg
- Price
- $880
- Updated
- 2021/12/16
- Product number
- DC10335
- Product name
- BGB-3111
- Purity
- >98%
- Packaging
- 100mg
- Price
- $900
- Updated
- 2021/12/16
- Product number
- DC10335
- Product name
- BGB-3111
- Purity
- >98%
- Packaging
- 250mg
- Price
- $1800
- Updated
- 2021/12/16
7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical Properties,Usage,Production
Uses
(±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC50 of 0.63 nM[1].
in vivo
(±)-Zanubrutinib induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts. Preliminary 14-day toxicity study in rats shows that (±)-Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250mg/kg/day[1].
References
[1] Na L, et al. BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2597. doi:10.1158/1538-7445.AM2015-2597